BTG plc acquires, develops, manufactures, and commercializes pharmaceutical products in the United States, Europe, and internationally. The company operates through three segments: Interventional Medicine, Specialty Pharmaceuticals, and Licensing segments. The Interventional Medicine segment offers interventional oncology products, such as bead products and TheraSphere for treatment of liver cancer; interventional vascular products consisting of EkoSonic for treatment of blood clots and Varithena for the treatment of varicoseveins; and interventional pulmonology products, including PneumRx Coil for advanced emphysema, a debilitating lung disease. The Specialty Pharmaceuticals segment provides antidote products, such as CroFab for the treatment of envenomations from the copperhead snake; DigiFab for the treatment of digoxin toxicity; Voraxaze for high-dose methotrexate toxicity; and Vistogar for the treatment of side effects of overexposure to the chemotherapeutic 5-fluorouracil. The Licensing segment offers Zytiga for treatment of prostate cancer; Two-Part Hip Cup for hip joint replacement; and Lemtrada for treatment of multiple sclerosis. BTG plc is developing a biodegradable bead product for use in non-malignant tumours, such as uterine fibroids; and manufactures and commercializes therapeutic ultrasound devices. The company was founded in 1948 and is headquartered in London, the United Kingdom.
btg plc (BTG:London Stock Exchange)
5 Fleet Place
London, EC4M 7RD
Phone: 44 20 7575 0000
Fax: 44 20 7575 0010www.btgplc.com
The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content.
|No competitor information is available for BTG.|
|View Industry Companies|
Sponsored Financial Commentaries
To contact BTG PLC, please visit www.btgplc.com. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.